Insmed Inc (INSM)vsXeris Pharmaceuticals Inc (XERS)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
XERS
Xeris Pharmaceuticals Inc
$5.30
+0.19%
HEALTHCARE · Cap: $938.03M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 108% more annual revenue ($606.42M vs $291.85M). XERS leads profitability with a 0.2% profit margin vs -2.1%. XERS earns a higher WallStSmart Score of 40/100 (F).
INSM
Hold39
out of 100
Grade: F
XERS
Hold40
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 42.8% year-over-year
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.2% margin — thin
Trading at 66.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : XERS
The strongest argument for XERS centers on Revenue Growth. Revenue growth of 42.8% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : XERS
The primary concerns for XERS are EPS Growth, Market Cap, Profit Margin. Thin 0.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while XERS is a hypergrowth play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
XERS is growing revenue faster at 42.8% — sustainability is the question.
XERS generates stronger free cash flow (20M), providing more financial flexibility.
Bottom Line
XERS scores higher overall (40/100 vs 39/100) and 42.8% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Xeris Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. The company is headquartered in Chicago, Illinois.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?